SXTP
60 Degrees Pharmaceuticals Inc (SXTP)
Healthcare • NASDAQ • $1.54-2.53%
- Symbol
- SXTP
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.54
- Daily Change
- -2.53%
- Market Cap
- $4.06M
- Trailing P/E
- N/A
- Forward P/E
- -0.20
- 52W High
- $14.68
- 52W Low
- $1.29
- Analyst Target
- $14.10
- Dividend Yield
- N/A
- Beta
- 2.70
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceutica…
Company websiteResearch SXTP on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.